Mevalonate pathway components KEAP1, NCOA4, SREBF2, and HMGCR show protective roles, suggesting a potential survival benefit with higher expression, which could relate to metabolic adaptation mechanisms in GBM. This evidence concerns the gene SREBF2 and glioblastoma.